• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Tyra Biosciences’ (TYRA) Dabogratinib 3×3 Focus Reframing Its Risk Reward Profile?

    Simply Wall St·05/16/2026 15:36:32
    Listen to the news
    • Tyra Biosciences, Inc. recently reported first-quarter 2026 results showing a wider net loss of US$39.31 million and basic loss per share of US$0.64, while highlighting progress across three Phase 2 trials for its lead candidate dabogratinib and a cash balance of US$383.5 million supporting operations into the second half of 2028.
    • An interesting angle for investors is how Tyra’s “dabogratinib 3×3” plan concentrates resources on three FGFR3-driven indications, potentially shaping its future path toward registration and commercialization decisions.
    • We’ll now examine how this focused dabogratinib 3×3 development strategy influences Tyra Biosciences’ broader investment narrative for investors.

    The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

    What Is Tyra Biosciences' Investment Narrative?

    To own Tyra Biosciences today, you really have to believe in the value of its focused “dabogratinib 3×3” plan: three FGFR3-driven indications, one oral asset, and a balance sheet that can support the effort. The latest quarter reinforced both sides of that equation. The company is leaning harder into its Phase 2 programs, with a wider US$39.31 million loss and no revenue, but the cash runway of US$383.5 million into the second half of 2028 gives it room to see key readouts from SURF302, BEACH301, and SURF303. Those milestones remain the main near term share price catalysts, and the new data timeline and first-patient dosing update look incrementally positive rather than thesis changing. The bigger swing factor is still binary clinical and regulatory risk around dabogratinib.

    However, that long cash runway and rising losses carry implications investors should not ignore. Our comprehensive valuation report raises the possibility that Tyra Biosciences is priced higher than what may be justified by its financials.

    Exploring Other Perspectives

    TYRA 1-Year Stock Price Chart
    TYRA 1-Year Stock Price Chart
    With just 1 fair value estimate from the Simply Wall St Community at US$15, you can see how differently individual investors might view Tyra’s potential. Set that alongside the current focus on dabogratinib trial outcomes and funding runway, and it becomes clear that understanding several viewpoints could be crucial for judging how the story evolves from here.

    Explore another fair value estimate on Tyra Biosciences - why the stock might be worth as much as $15.00!

    Form Your Own Verdict

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    No Opportunity In Tyra Biosciences?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.